RU2704999C2 - Способ лечения кожной инфекции путем введения антагониста il-4r - Google Patents
Способ лечения кожной инфекции путем введения антагониста il-4r Download PDFInfo
- Publication number
- RU2704999C2 RU2704999C2 RU2016130056A RU2016130056A RU2704999C2 RU 2704999 C2 RU2704999 C2 RU 2704999C2 RU 2016130056 A RU2016130056 A RU 2016130056A RU 2016130056 A RU2016130056 A RU 2016130056A RU 2704999 C2 RU2704999 C2 RU 2704999C2
- Authority
- RU
- Russia
- Prior art keywords
- baseline
- day
- days
- change
- skin
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 77
- 206010040872 skin infection Diseases 0.000 title claims abstract description 49
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 67
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 67
- 239000000427 antigen Substances 0.000 claims abstract description 51
- 108091007433 antigens Proteins 0.000 claims abstract description 51
- 102000036639 antigens Human genes 0.000 claims abstract description 51
- 230000027455 binding Effects 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 47
- 239000012634 fragment Substances 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 35
- 208000015181 infectious disease Diseases 0.000 claims abstract description 27
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 20
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 11
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 10
- 241000194017 Streptococcus Species 0.000 claims abstract description 7
- 206010021531 Impetigo Diseases 0.000 claims abstract description 6
- 206010007882 Cellulitis Diseases 0.000 claims abstract description 5
- 206010016936 Folliculitis Diseases 0.000 claims abstract description 5
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 5
- 230000002458 infectious effect Effects 0.000 claims abstract description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 4
- 208000024386 fungal infectious disease Diseases 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 229940124597 therapeutic agent Drugs 0.000 claims description 21
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 239000003246 corticosteroid Substances 0.000 claims description 8
- 229950003468 dupilumab Drugs 0.000 claims description 8
- 229940123418 Interleukin 4 receptor antagonist Drugs 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 239000003429 antifungal agent Substances 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 208000007712 Tinea Versicolor Diseases 0.000 claims description 3
- 206010056131 Tinea versicolour Diseases 0.000 claims description 3
- 229940090047 auto-injector Drugs 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 201000000508 pityriasis versicolor Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 71
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 201000010099 disease Diseases 0.000 abstract description 14
- 238000007920 subcutaneous administration Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 210000000434 stratum corneum Anatomy 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 3
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 abstract 3
- 238000013016 damping Methods 0.000 abstract 1
- 230000008859 change Effects 0.000 description 234
- 239000000902 placebo Substances 0.000 description 78
- 229940068196 placebo Drugs 0.000 description 78
- 208000003251 Pruritus Diseases 0.000 description 71
- 210000003491 skin Anatomy 0.000 description 61
- 238000002347 injection Methods 0.000 description 27
- 239000007924 injection Substances 0.000 description 27
- 238000012216 screening Methods 0.000 description 27
- 230000036572 transepidermal water loss Effects 0.000 description 24
- 244000005700 microbiome Species 0.000 description 22
- 230000007423 decrease Effects 0.000 description 19
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 230000004888 barrier function Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 230000007803 itching Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 230000002378 acidificating effect Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 102000004388 Interleukin-4 Human genes 0.000 description 11
- 108090000978 Interleukin-4 Proteins 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 230000003442 weekly effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000009467 reduction Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000001647 drug administration Methods 0.000 description 8
- 238000002565 electrocardiography Methods 0.000 description 8
- 210000004602 germ cell Anatomy 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000008591 skin barrier function Effects 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000009534 blood test Methods 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 4
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 102000025171 antigen binding proteins Human genes 0.000 description 4
- 108091000831 antigen binding proteins Proteins 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 229940046731 calcineurin inhibitors Drugs 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000037081 physical activity Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 3
- 108010083698 Chemokine CCL26 Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000035874 Excoriation Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 3
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001480037 Microsporum Species 0.000 description 3
- 241000700560 Molluscum contagiosum virus Species 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 241000223238 Trichophyton Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 241000223600 Alternaria Species 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- AIRYAONNMGRCGJ-FHFVDXKLSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC AIRYAONNMGRCGJ-FHFVDXKLSA-N 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 241000222290 Cladosporium Species 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 206010024438 Lichenification Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000746 body region Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- -1 ethanol) Chemical compound 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 208000037851 severe atopic dermatitis Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001150 spermicidal effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 101001023095 Anemonia sulcata Delta-actitoxin-Avd1a Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101000641989 Araneus ventricosus Kunitz-type U1-aranetoxin-Av1a Proteins 0.000 description 1
- 206010064823 Asthmatic crisis Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 101001028691 Carybdea rastonii Toxin CrTX-A Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 101000685083 Centruroides infamatus Beta-toxin Cii1 Proteins 0.000 description 1
- 101000685085 Centruroides noxius Toxin Cn1 Proteins 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 101001028688 Chironex fleckeri Toxin CfTX-1 Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 101000644407 Cyriopagopus schmidti U6-theraphotoxin-Hs1a Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 1
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 102100037765 Periostin Human genes 0.000 description 1
- 101710199268 Periostin Proteins 0.000 description 1
- 101000679608 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) Cysteine rich necrotrophic effector Tox1 Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000009811 bilateral tubal ligation Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- 230000010093 eczematous lesion Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940015979 epipen Drugs 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001314 profilometry Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- QHGVXILFMXYDRS-UHFFFAOYSA-N pyraclofos Chemical compound C1=C(OP(=O)(OCC)SCCC)C=NN1C1=CC=C(Cl)C=C1 QHGVXILFMXYDRS-UHFFFAOYSA-N 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946237P | 2014-02-28 | 2014-02-28 | |
| US61/946,237 | 2014-02-28 | ||
| US201461952245P | 2014-03-13 | 2014-03-13 | |
| US61/952,245 | 2014-03-13 | ||
| US201461986371P | 2014-04-30 | 2014-04-30 | |
| US61/986,371 | 2014-04-30 | ||
| EP14306476.4 | 2014-09-24 | ||
| EP14306476 | 2014-09-24 | ||
| US201562100128P | 2015-01-06 | 2015-01-06 | |
| US62/100,128 | 2015-01-06 | ||
| PCT/US2015/017834 WO2015130975A1 (en) | 2014-02-28 | 2015-02-26 | Methods for treating skin infection by administering an il-4r antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016130056A RU2016130056A (ru) | 2018-04-02 |
| RU2016130056A3 RU2016130056A3 (cg-RX-API-DMAC7.html) | 2018-11-12 |
| RU2704999C2 true RU2704999C2 (ru) | 2019-11-01 |
Family
ID=51663113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016130056A RU2704999C2 (ru) | 2014-02-28 | 2015-02-26 | Способ лечения кожной инфекции путем введения антагониста il-4r |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10370449B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3110848B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6526037B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20160120735A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106062000B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015222951B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2939506C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2973858T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX376691B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3110848T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3110848T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2704999C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015130975A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2845158C1 (ru) * | 2020-03-27 | 2025-08-13 | Ридженерон Фармасьютикалз, Инк. | Способы лечения атопического дерматита путем введения антагониста il-4r |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN104755495A (zh) | 2012-08-21 | 2015-07-01 | 赛诺菲 | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 |
| RU2698907C2 (ru) | 2012-09-07 | 2019-09-02 | Ридженерон Фармасьютикалз, Инк. | Способы лечения атопического дерматита с помощью антагониста il-4r |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| MX376691B (es) | 2014-02-28 | 2025-03-07 | Regeneron Pharma | Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea. |
| KR20230158131A (ko) | 2014-11-14 | 2023-11-17 | 사노피 바이오테크놀로지 | Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법 |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| PT3506931T (pt) | 2016-09-01 | 2024-08-21 | Regeneron Pharma | Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| US12208124B2 (en) * | 2017-09-05 | 2025-01-28 | Azitra Inc. | Methods and compositions for treating inflammatory skin disease with recombinant microorganisms |
| KR102694419B1 (ko) | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| SG11202009371WA (en) | 2018-05-13 | 2020-10-29 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| US11312778B2 (en) | 2018-11-21 | 2022-04-26 | Brian C. Machler | Method for treating allergic contact dermatitis |
| CN111514292B (zh) | 2018-12-25 | 2023-06-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
| WO2020180727A1 (en) * | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| US12398212B2 (en) | 2019-07-16 | 2025-08-26 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| EP3992974A1 (en) * | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
| JP2023504204A (ja) * | 2019-12-09 | 2023-02-01 | サノフィ・バイオテクノロジー | デジタル的に識別されたｉｌ－４／ｉｌ－１３関連障害を治療する方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001092340A2 (en) * | 2000-05-26 | 2001-12-06 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
| EA011302B1 (ru) * | 2003-11-07 | 2009-02-27 | Иммунекс Корпорейшн | Антитела, которые связывают рецептор интерлейкина-4 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| AU665763B2 (en) | 1991-05-03 | 1996-01-18 | Seragen, Inc. | Interleukin receptor targeted molecules for treatment of inflammatory arthritis |
| JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
| US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| RU2162711C2 (ru) | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
| JP2003524602A (ja) | 1998-09-18 | 2003-08-19 | ダイナバックス テクノロジーズ コーポレイション | ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物 |
| US20020002132A1 (en) * | 2000-05-26 | 2002-01-03 | Pluenneke John D. | Use of interleukin-4 antagonists and compositions thereof |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| KR100572408B1 (ko) | 2000-07-26 | 2006-04-19 | 가부시키가이샤 호오도 | 진양성 조성물 및 창상치유촉진 조성물 |
| US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
| JP2004529180A (ja) | 2001-05-11 | 2004-09-24 | ノバルティス アクチエンゲゼルシャフト | ＩｇＥ関連障害を処置するのに使用するための組成物 |
| EP1450855B1 (en) | 2001-05-23 | 2009-08-26 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| ATE517855T1 (de) | 2001-11-30 | 2011-08-15 | Biogen Idec Inc | Antikörper gegen chemotaktische monozytenproteine |
| DK1527100T3 (da) | 2002-03-29 | 2009-09-07 | Schering Corp | Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme |
| CA2514840C (en) | 2003-02-01 | 2017-11-07 | Tanox, Inc. | High affinity, anti-human ige antibodies |
| US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| AU2004309373A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| JP2008504806A (ja) | 2004-02-27 | 2008-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用 |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
| DK2769992T3 (da) | 2006-10-02 | 2021-03-22 | Regeneron Pharma | Humane antistoffer med høj affinitet for human IL-4-receptor |
| WO2008116149A2 (en) | 2007-03-22 | 2008-09-25 | Genentech, Inc. | Apoptotic anti- ige antibodies binding the membrane-bound ige |
| EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| WO2009061819A1 (en) | 2007-11-05 | 2009-05-14 | The Regents Of The University Of Colorado | Minimally-invasive measurement of esophageal inflammation |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| US20120004205A1 (en) | 2008-12-01 | 2012-01-05 | Cincinnati Children's Hospital Medical Center | Il-13 induced gene signature for eosinophilic esophagitis |
| EP2414520A2 (en) | 2009-03-31 | 2012-02-08 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
| US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
| CN102596237A (zh) | 2009-09-07 | 2012-07-18 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
| US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
| EP2585075B8 (en) | 2010-06-24 | 2021-09-22 | ViroPharma Biologics LLC | Methods of treatment for esophageal inflammation |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| RU2453303C1 (ru) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
| US20130324435A1 (en) | 2011-01-06 | 2013-12-05 | Children's Hospital Medical Center | Esophageal cytokine expression profiles in eosinophilic esophagitis |
| US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| US9928344B2 (en) | 2011-06-21 | 2018-03-27 | Children's Hospital Medical Center | Diagnostic methods of eosinophilic esophagitis |
| EP2763683A1 (en) | 2011-10-06 | 2014-08-13 | N.V. Nutricia | Treatment of eosinophilic esophagitis |
| US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
| TW201334789A (zh) | 2012-01-31 | 2013-09-01 | Genentech Inc | 抗ｉｇｅ抗體及其使用方法 |
| WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
| CN104755495A (zh) | 2012-08-21 | 2015-07-01 | 赛诺菲 | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 |
| RU2698907C2 (ru) | 2012-09-07 | 2019-09-02 | Ридженерон Фармасьютикалз, Инк. | Способы лечения атопического дерматита с помощью антагониста il-4r |
| WO2014059178A1 (en) | 2012-10-10 | 2014-04-17 | Rhode Island Hospital | Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis |
| EP3620468A1 (en) | 2013-02-05 | 2020-03-11 | EngMab Sàrl | Method for the selection of antibodies against bcma |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| PL3010539T3 (pl) | 2013-06-21 | 2020-01-31 | Sanofi Biotechnology | Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| MX376691B (es) | 2014-02-28 | 2025-03-07 | Regeneron Pharma | Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea. |
| KR20230158131A (ko) | 2014-11-14 | 2023-11-17 | 사노피 바이오테크놀로지 | Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법 |
| CN109069625A (zh) | 2016-02-19 | 2018-12-21 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂来增强疫苗功效的方法 |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| PT3506931T (pt) | 2016-09-01 | 2024-08-21 | Regeneron Pharma | Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r |
| RU2759630C2 (ru) | 2016-09-22 | 2021-11-16 | Ридженерон Фармасьютикалз, Инк. | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r |
| EP3582782B1 (en) | 2017-02-17 | 2023-06-07 | Fred Hutchinson Cancer Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| KR102694419B1 (ko) | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| SG11202009371WA (en) | 2018-05-13 | 2020-10-29 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| JP2023504204A (ja) | 2019-12-09 | 2023-02-01 | サノフィ・バイオテクノロジー | デジタル的に識別されたｉｌ－４／ｉｌ－１３関連障害を治療する方法 |
| IL298257A (en) | 2020-05-22 | 2023-01-01 | Regeneron Pharma | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| US20220220211A1 (en) | 2021-01-08 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist |
-
2015
- 2015-02-26 MX MX2016011132A patent/MX376691B/es active IP Right Grant
- 2015-02-26 CA CA2939506A patent/CA2939506C/en active Active
- 2015-02-26 US US14/632,988 patent/US10370449B2/en active Active
- 2015-02-26 WO PCT/US2015/017834 patent/WO2015130975A1/en not_active Ceased
- 2015-02-26 PT PT157106501T patent/PT3110848T/pt unknown
- 2015-02-26 CN CN201580010895.XA patent/CN106062000B/zh active Active
- 2015-02-26 JP JP2016553322A patent/JP6526037B2/ja active Active
- 2015-02-26 PL PL15710650.1T patent/PL3110848T3/pl unknown
- 2015-02-26 RU RU2016130056A patent/RU2704999C2/ru active
- 2015-02-26 KR KR1020167023138A patent/KR20160120735A/ko not_active Ceased
- 2015-02-26 KR KR1020227016206A patent/KR102695088B1/ko active Active
- 2015-02-26 EP EP15710650.1A patent/EP3110848B1/en active Active
- 2015-02-26 ES ES15710650T patent/ES2973858T3/es active Active
- 2015-02-26 KR KR1020247026710A patent/KR20240128110A/ko active Pending
- 2015-02-26 EP EP23219610.5A patent/EP4353254A3/en active Pending
- 2015-02-26 AU AU2015222951A patent/AU2015222951B2/en active Active
-
2019
- 2019-05-28 US US16/424,094 patent/US11603408B2/en active Active
-
2020
- 2020-06-29 AU AU2020204350A patent/AU2020204350B2/en active Active
-
2023
- 2023-02-06 US US18/165,203 patent/US20230357416A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001092340A2 (en) * | 2000-05-26 | 2001-12-06 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
| US20030124121A1 (en) * | 2000-05-26 | 2003-07-03 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
| EA011302B1 (ru) * | 2003-11-07 | 2009-02-27 | Иммунекс Корпорейшн | Антитела, которые связывают рецептор интерлейкина-4 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
Non-Patent Citations (9)
| Title |
|---|
| "Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis", 71 ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY, 02.03.2013, pages 1-3, Найдено в Интернет [12/11/2018] https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-proof-concept-data/. * |
| doi:10.1517/14728214.2012.668884. "Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis", 71 ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY, 02.03.2013, pages 1-3, Найдено в Интернет [12/11/2018] https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-proof-concept-data/. 7, no.5, p.729-734. * |
| LIN YU-TSAN ET AL. "Role of bacterial pathogens in atopic dermatitis", CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2007, v.33, no.3, p.167-177. * |
| NAVARINI A. A. et al. "Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection". J ALLERGY CLIN IMMUNOL, NOVEMBER 2011, 128(5):1128-30, doi:10.1016/j.jaci.2011.09.009. * |
| ONG P. Y. "Editorial update on emerging treatments of atopic dermatitis". Expert Opinion on Emerging Drugs, 2012, 17(2), p.129-133. * |
| ONG P. Y. "Editorial update on emerging treatments of atopic dermatitis". Expert Opinion on Emerging Drugs, 2012, 17(2), p.129-133. doi:10.1517/14728214.2012.668884. * |
| PETRY V. ET AL. "Bacterial skin colonization and infections in patients with atopic dermatitis", ANAIS BRASILEIROS DE DERMATOLOGIA, 2012, v.8 * |
| RING J. et al. "Guidelines for treatment of atopic eczema (atopic dermatitis) Part I". Journal of the European Academy of Dermatology and Venereology, 2012, 26(8), 1045-1060. doi:10.1111/j.1468-3083.2012.04635.x. * |
| RING J. et al. "Guidelines for treatment of atopic eczema (atopic dermatitis) Part I". Journal of the European Academy of Dermatology and Venereology, 2012, 26(8), 1045-1060. doi:10.1111/j.1468-3083.2012.04635.x. PETRY V. ET AL. "Bacterial skin colonization and infections in patients with atopic dermatitis", ANAIS BRASILEIROS DE DERMATOLOGIA, 2012, v.87, no.5, p.729-734. LIN YU-TSAN ET AL. "Role of bacterial pathogens in atopic dermatitis", CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2007, v.33, no.3, p.167-177. NAVARINI A. A. et al. "Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection". J ALLERGY CLIN IMMUNOL, NOVEMBER 2011, 128(5):1128-30, doi:10.1016/j.jaci.2011.09.009. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2845158C1 (ru) * | 2020-03-27 | 2025-08-13 | Ридженерон Фармасьютикалз, Инк. | Способы лечения атопического дерматита путем введения антагониста il-4r |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2973858T3 (es) | 2024-06-24 |
| CA2939506A1 (en) | 2015-09-03 |
| CA2939506C (en) | 2022-08-23 |
| CN106062000B (zh) | 2021-05-28 |
| EP4353254A2 (en) | 2024-04-17 |
| US20190367622A1 (en) | 2019-12-05 |
| PT3110848T (pt) | 2024-03-05 |
| MX376691B (es) | 2025-03-07 |
| JP2017512193A (ja) | 2017-05-18 |
| US11603408B2 (en) | 2023-03-14 |
| US20150246973A1 (en) | 2015-09-03 |
| US20230357416A1 (en) | 2023-11-09 |
| EP3110848B1 (en) | 2024-02-14 |
| AU2015222951B2 (en) | 2020-06-11 |
| EP4353254A3 (en) | 2024-07-03 |
| RU2016130056A3 (cg-RX-API-DMAC7.html) | 2018-11-12 |
| KR20220070544A (ko) | 2022-05-31 |
| EP3110848A1 (en) | 2017-01-04 |
| US10370449B2 (en) | 2019-08-06 |
| AU2020204350A1 (en) | 2020-07-16 |
| AU2020204350B2 (en) | 2023-03-23 |
| RU2016130056A (ru) | 2018-04-02 |
| MX2016011132A (es) | 2016-12-08 |
| WO2015130975A1 (en) | 2015-09-03 |
| PL3110848T3 (pl) | 2024-06-10 |
| KR20240128110A (ko) | 2024-08-23 |
| JP6526037B2 (ja) | 2019-06-05 |
| CN106062000A (zh) | 2016-10-26 |
| KR20160120735A (ko) | 2016-10-18 |
| KR102695088B1 (ko) | 2024-08-16 |
| AU2015222951A1 (en) | 2016-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2704999C2 (ru) | Способ лечения кожной инфекции путем введения антагониста il-4r | |
| US11518804B2 (en) | Method of treating osteoarthritis with an antibody to NGF | |
| RU2698907C2 (ru) | Способы лечения атопического дерматита с помощью антагониста il-4r | |
| JP2024038234A (ja) | Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 | |
| Kragballe | Management of difficult to treat locations of psoriasis | |
| US20230167171A1 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| TW202045537A (zh) | 化膿性汗腺炎的治療 | |
| HK40102414A (en) | Methods for treating skin infection by administering an il-4r antagonist | |
| RU2801204C2 (ru) | Способ лечения атопического дерматита посредством введения ингибитора ил-4r | |
| RU2828020C2 (ru) | Способы лечения атопического дерматита посредством введения антагониста il-4r | |
| HK1228934B (en) | Methods for treating skin infection by administering an il-4r antagonist | |
| HK1228934A1 (en) | Methods for treating skin infection by administering an il-4r antagonist | |
| KR20200069388A (ko) | Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법 |